The imbalance between Type 17 T-cells and regulatory immune cell subsets in psoriasis vulgaris

Front Immunol. 2022 Aug 30:13:1005115. doi: 10.3389/fimmu.2022.1005115. eCollection 2022.

Abstract

Psoriasis vulgaris is a common inflammatory disease affecting 7.5 million adults just in the US. Previously, psoriasis immunopathogenesis has been viewed as the imbalance between CD4+ T-helper 17 (Th17) cells and regulatory T-cells (Tregs). However, current paradigms are rapidly evolving as new technologies to study immune cell subsets in the skin have been advanced. For example, recently minted single-cell RNA sequencing technology has provided the opportunity to compare highly differing transcriptomes of Type 17 T-cell (T17 cell) subsets depending on IL-17A vs. IL-17F expression. The expression of regulatory cytokines in T17 cell subsets provided evidence of T-cell plasticity between T17 cells and regulatory T-cells (Tregs) in humans. In addition to Tregs, other types of regulatory cells in the skin have been elucidated, including type 1 regulatory T-cells (Tr1 cells) and regulatory dendritic cells. More recently, investigators are attempting to apply single-cell technologies to clinical trials of biologics to test if monoclonal blockade of pathogenic T-cells will induce expansion of regulatory immune cell subsets involved in skin homeostasis.

Keywords: immune homeostasis; immune tolerance; psoriasis; regulator T-cell; regulatory dendritic cell; type 1 regulatory T-cell; type 17 T-cells.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biological Products* / therapeutic use
  • Cytokines / metabolism
  • Humans
  • Interleukin-17 / metabolism
  • Psoriasis*
  • Th17 Cells

Substances

  • Biological Products
  • Cytokines
  • Interleukin-17